OraSure Technologies, Inc. (NASDAQ:OSUR) is expected to report third quarter earnings results, after market close, on Wednesday 4th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.07 per share.
Looking ahead, the full year loss are expected at $ 0.26 per share on the revenues of $ 165.29 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 145.00 million ~ $ 155.00 million, where as bottomline are predicted in a range of $ -0.10 ~ $ -0.07 per share
Click Here For More Historical Outlooks Of OraSure Technologies, Inc.
Previous Quarter Performance
OraSure Technologies, Inc. communicated loss for the second quarter of $ 0.16 per share, from the revenue of $ 29.26 million. Street analysts expected OraSure Technologies, Inc. to report loss of $ 0.09 per share on revenue of $ 32.82 million for the second quarter. The bottom line results missed street analysts by $ 0.07 or 77.78 percent, at the same time, top line results fell short of analysts by $ 3.56 million or 10.85 percent.
Stock Performance
Shares of OraSure Technologies, Inc. traded up $ 0.10 or 0.64 percent on Tuesday, reaching $ 14.98 with volume of 1.45 million shares. OraSure Technologies, Inc. has traded high as $ 15.49 and has cracked $ 14.75 on the downward trend
According to the previous trading day, closing price of $ 14.98, representing a 184.70 % increase from the 52 week low of $ 5.23 and a 24.61 % decrease over the 52 week high of $ 19.75.
The company has a market capital of $ 1.07 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
OraSure Technologies, Inc. will be hosting a conference call at 12:00 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.orasure.com
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
